Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Neovascular age-related macular degeneration

5 evidence topics · 4 sources

Global prevalence and projected growth

“the number of people suffering from AMD is expected to increase from 196 million in 2020 to 288 million in 2040” (opens the source at this quote in a new tab)

Prevalence in a population-based cohort

“The prevalence of nAMD was 862 (/100,000 inhabitants) (95% CI 821–906) in adults aged 44–96 years in 2020.” (opens the source at this quote in a new tab)

“In the oldest 75–84 and 85–96 age categories the nAMD prevalence was 2865/100,000 (3%, 95% CI 2665–3079) and 2620/100,000 (3%, 95% CI 2323–2956), respectively.” (opens the source at this quote in a new tab)

United States prevalence among Medicare beneficiaries

“the prevalence of wet AMD remained relatively stable, fluctuating from 2.17% in 2014 to 2.14% in 2021.” (opens the source at this quote in a new tab)

Prevalence by race and ethnicity

“the prevalence of wet AMD showed a progressive decrease across White, Native American, Asian, Hispanic, and Black populations” (opens the source at this quote in a new tab)

United States burden estimates

“Nearly 20 million U.S. adults are living with some form of age-related macular degeneration.” (opens the source at this quote in a new tab)

“Wet macular degeneration accounts for approximately 10% of all AMD cases but is responsible for 90% of legal blindness.” (opens the source at this quote in a new tab)